Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.59 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61507 | 1.00 | HTR6 (0.59) | HTR6HTR2ARETADRA2AADRA2B | |
| SCHEMBL29681415 | 1.00 | HTR6 (0.59) | HTR6HTR2ARETADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL15818880 | 0.98 | HTR6 (0.57) | HTR6HTR2ARETADRA2AADRA2B | |
| SCHEMBL643387 | 0.88 | HTR6 (0.56) | HTR6HTR2ARETIDO1 | |
| Hydrochloric Acid SCHEMBL27196405 | 0.86 | HTR6 (0.55) | HTR6HTR2ARETIDO1 | |
| SCHEMBL428148 | 0.86 | HTR2A (0.53) | HTR6HTR2ARETIDO1 | |
| SCHEMBL8901289 | 0.85 | HTR6 (0.47) | HTR6HTR2ARETADRA2AADRA2B | |
| SCHEMBL29655195 | 0.84 | HTR6 (0.56) | HTR6HTR2ARETIDO1HRH1 | |
| SCHEMBL7379841 | 0.84 | HTR6 (0.56) | HTR6HTR2ARETIDO1HRH1 | |
| SCHEMBL27488330 | 0.81 | HTR6 (0.56) | HTR6HTR2ARETADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118702580-A | Preparation method of 1-aminoindan hydrochloride | 合肥菁科生物科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| US-6562840-B1 | Non-peptidic inhibitors of proteolytic enzymes such as urokinase | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | claimed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | claimed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | claimed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | claimed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| JP-9040621-A | — | — | None | — | — | JP | disclosed |
| CN-118702580-A | Preparation method of 1-aminoindan hydrochloride | 合肥菁科生物科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118702580-A | Preparation method of 1-aminoindan hydrochloride | 合肥菁科生物科技有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-113121534-B | Organic small molecule electron transport material based on naphthalene diimide unit and application thereof | 中国科学院长春应用化学研究所 | 2022-06-07 | — | — | CN | disclosed |
| US-11289238-B2 | Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2022-03-29 | — | — | US | disclosed |
| CN-113121534-A | Organic small-molecule electron transport material based on naphthalene diimide unit and application thereof | 中国科学院长春应用化学研究所 | 2021-07-16 | — | — | CN | disclosed |
| US-20210174983-A1 | COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC | 2021-06-10 | — | — | US | disclosed |
| EP-0281261-A2 | 3-Aminomethyl derivatives of indane, indoline and dihydrobenzofurane and dihydrobenzothiophene | H. LUNDBECK A/S (DK) | 1988-09-07 | — | — | EP | disclosed |
| US-4769368-A | DOPAMINE ANTAGONISTS | SMITHKLINE BECKMAN CORPORATION (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0233049-A1 | 2,3,4,8,9,9a-Hexahydro-4-aryl-1H-indeno[1,7-cd]azepines | SMITHKLINE BECKMAN CORPORATION (US) | 1987-08-19 | — | — | EP | disclosed |
| EP-0179667-A2 | N6-substituted adenosines | WARNER-LAMBERT COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
| US-4505932-A | AMINOMETHYL-DIHYDROXY (DIALKOXY)-INDOLE, HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1985-03-19 | — | — | US | disclosed |
| US-3886168-A | HYPOTENSIVE AGENTS, ANTIINFLAMMATORY AGENTS, STIMULANTS | BASF AG | 1975-05-27 | — | — | US | disclosed |
| US-3886168-A | HYPOTENSIVE AGENTS, ANTIINFLAMMATORY AGENTS, STIMULANTS | BASF AG | 1975-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | HTR6 769/4885HTR2A 956/4885RET 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.